@article{JTD20891,
author = {Hengrui Liang and Zhenkui Pan and Wei Wang and Chengye Guo and Difei Chen and Jianrong Zhang and Yiyin Zhang and Shiyan Tang and Jianxing He and Wenhua Liang and written on behalf of AME Lung Cancer Cooperative Group},
title = {The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {4},
year = {2018},
keywords = {},
abstract = {Background: Treatment-naive epidermal growth factor receptor (EGFR) T790M mutation is more inclined to coexist with L858R than with 19 del in non-small cell lung cancer (NSCLC) patients. However, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) might alter this status. We sought to compare the prevalence of T790M upon acquired resistance to EGFR-TKIs between 19 del and L858R by assembling all existing data.
Methods: Electronic databases were comprehensively searched for eligible studies. The primary endpoint was the odds ratio (OR) of T790M mutation in NSCLC co-existing with L858R mutation and 19 del upon resistance to first-generation EGFR-TKIs. A random effects model was used. Stratified analysis was performed based on study type (retrospective and prospective), race (Asians and Caucasians) and sample type (tissue and plasma).
Results: A total of 25 studies involving 1,770 patients were included. The overall T790M existent rate was 45.25%. Post-resistance T790M was more frequent in 19 del than in L858R mutated patients (53% vs. 36%; OR 1.87; P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/20891}
}